General Resources / Legal Resources / Medical Resources / Briefing Papers / State
Activity
Hospital Closures / Preventable
Tragedies / Press Room / Search Our Site / Home
Testimony on Kendra's Law
Testimony of:
Marvin Swartz
Professor of Psychiatry
Duke University
Durham, NC
before the
Assembly Standing Committee on Mental Health, Mental Retardation and Developmental Disabilities
April 8, 2005
Good morning, Chairman Rivera, Chairman Lentol and members of the Assembly Standing Committees on Mental Health, Mental Retardation, and Developmental Disabilities, the Committee on Codes and others in attendance.
My name is Dr. Marvin Swartz and it’s a pleasure to have the opportunity to discuss Kendra’s Law with you this morning. I am a Professor of Psychiatry at Duke University in Durham, NC, where, for over 15 years, we have conducted research on North Carolina’s version of assisted outpatient treatment (AOT) or involuntary outpatient commitment, as we refer to it in North Carolina. I am also psychiatrist and have treated persons with severe mental illness for nearly 25 years. We are very cognizant of the serious civil liberties concerns raised by AOT. As a result we try to conduct independent research that informs the public about how these laws affect treatment outcomes for consumers. Our research group is University-based and as independent investigators we have no advocacy position for or against AOT.
Our research group conducted the first randomized controlled trial of AOT and we were members of the research team who conducted the Bellevue AOT Study prior to enactment of Kendra’s Law. I am also a member of the MacArthur Foundation Research Network on Mandated Community Treatment which studies these laws and related public policies.
I would like to take a few moments to review what we have concluded about the effectiveness of laws such as Kendra’s Law and review some of the research that may be helpful in your deliberations about the future of Kendra’s Law in New York State. I will not discuss the Bellevue Study because its findings will be discussed by others. It is our view that the Bellevue Study was conducted on too small a scale and too early in the development of the AOT program to be conclusive—if only because enforcement of AOT was not in place during the study.
Our research team has conducted a number of studies of the effectiveness of our version of AOT. We have had the current version of the law since 1984. In our first experimental study, conducted in North Carolina, roughly 250 individuals with severe mental illness were randomly assigned to receive community mental health services with AOT or comparable community services without AOT. Our objective was to study whether AOT provided any benefit over and above the benefit of consistent community services. We studied severely mentally ill consumers for 12 months and interviewed consumers, their families and their clinicians to understand each person’s view of the effectiveness of AOT and what other benefits or detrimental effects a result of AOT. This is what we found:
To accomplish this we interviewed a randomly selected group of consumers with schizophrenia, family members of consumers with schizophrenia, clinicians treating consumers with schizophrenia and members of the general public. We asked each set of stakeholders to rate the importance of concerns about the pros and cons of AOT. In effect, the question we asked was “if AOT has the benefits of reducing hospitalization, reducing family strain, and reducing violence, is it worth it to trade-off the loss of liberty under AOT to gain these benefits?”
To our surprise, each of these groups agreed that AOT was a reasonable price to pay to reduce hospitalizations, family strain and violence. We then asked these consumers with schizophrenia whether they thought these types of legal policies were fair and effective. Approximately two-thirds of these randomly selected consumers with schizophrenia believed that these types of policies, like AOT, were effective, and over half, 55%, thought that using these policies with mentally ill consumers was fair. To be sure, consumers in New York may have different opinions about these policies and we may not have adequately studied consumers who have dropped out of treatment altogether.
In summary, we think the question is not whether laws like Kendra’s Law are effective or not. The question is: “under what conditions can laws like AOT be effective and at what personal costs?” Our work suggests that AOT can be effective when provided for 6 months or more and combined with consistent and frequent outpatient services and come with what the consumers we studied consider acceptable personal costs. Kendra’s Law is well aligned with research on how AOT can be effective - that is, by being applied over a reasonable length of time -- 6 months or more -- and by combining AOT with appropriate and frequent outpatient services. Our work suggests that you should continue to use AOT carefully, with the current legal safeguards and closely tie AOT to the assurance of appropriate services.
Thanks very much for the opportunity to speak with you today.
Marvin Swartz, M.D.
Professor of Psychiatry
Duke University Medical Center
Durham, N.C.
Email: [email protected]
FIND OUT MORE
Advocates page
general
resources | legal resources | medical
resources | briefing papers | state activity
hospital closures | preventable
tragedies | press room | search
| home
The contents of TAC's website are copyrighted by the Treatment Advocacy Center unless otherwise indicated. All rights reserved and content may be reproduced, downloaded, disseminated, or transferred, for single use, or by nonprofit organizations for educational purposes only, if correct attribution is made. TAC is an I.R.C. � 501(c)(3) tax-exempt corporation. Donations are appreciated and are eligible for the charitable contribution deduction under the provisions of I.R.C. � 170. Please note that TAC does not accept funding from pharmaceutical companies or entities involved in the sale, marketing, or distribution of such products.
Treatment Advocacy Center (TAC), 200 N. Glebe Road, Suite 730, Arlington, VA 22203 703 294 6001/6002 (phone) | 703 294 6010 (fax) | www.treatmentadvocacycenter.org (website) [email protected] (general email) | [email protected] (press contact) [email protected] (webmaster) |